Relypsa - Top 15 Biotech VC Deals of 2010

Company: Relypsa
Based: Santa Clara, CA
Amount: $70M

Investors: OrbiMed Advisors, New Leaf Venture Partners, 5AM Ventures, Delphi Ventures, Sprout Group and Mediphase Venture Partners

Scoop: Relypsa was founded by a group of ex-Ilypsa executives who got the rights to four preclinical programs they had been developing before Amgen bought the company for $420 million in 2009. Relypsa's lead compound is RLY5016, which the company's site describes as a "high capacity cation binder for the management of hyperkalemia in congestive heart failure (CHF) and chronic kidney disease (CKD) patients."

Relypsa's $70 million Series B provides the company with enough funding to see it through Phase III trials of RLY5016. Its total venture haul is more than $100 million.

Relypsa - Top 15 Biotech VC Deals of 2010
Read more on

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.